Two major pharmaceuticals combine to accelerate sales in emerging markets.

Leading pharmaceutical company, GlaxoSmithKline (GSK), has announced an agreement with Dr. Reddy’s Laboratories, to develop and market products across emerging markets, excluding India.

GV Prasad, Vice Chairman and CEO of Dr Reddy’s said: “We are extremely pleased to combine forces with GSK, a global leader, to fully realise the potential of our strengths in technology, product development and manufacturing across a range of high growth emerging markets.”

GSK President of Emerging Markets, Abbas Hussain, commented on the importance of the strategic partnership: “This is another significant step forward in our strategy to grow and diversify GSK’s business in emerging markets.”

Under the terms of the agreement, GSK will gain exclusive access to Dr Reddy’s portfolio and future pipeline of more than 100 branded pharmaceuticals. Dr Reddy’s extensive range includes therapeutic segments such as cardiovascular, diabetes, oncology, gastroenterology and pain management.  

GSK is one of the world’s leading research-based pharmaceutical and healthcare companies and employs around 99,000 people in over 100 countries. Mr Hussain continued: “Together we will be able to deliver more medicines of value to more patients in these countries.”

Dr. Reddy’s will take care of the manufacturing side of the partnership, while GSK will manage the licence and supply across various countries in Africa, the Middle East, Asia Pacific and Latin America.

Dr. Reddy’s markets its products globally with an existing focus in India, hence its exclusion in this agreement with GSK.